Molina Healthcare (MOH) has demonstrated strong momentum in the bio-tech market, recently hitting a 52 week high. The company has enjoyed a massive 52.5% surge in its share price over the past year. Several factors have contributed to its growth, including a favorable Medicaid deal with New Mexico Health Services Department, increasing membership, and positive adjustment of the EPS amid a revenue surge. Financial analyses reveal that it's significantly underrated, suggesting a potential of 35-37% undervaluation. MOH's acquisition of Magellan Health's unit and Bright Healthcare's California Medicare Business indicates expansion and diversification. However, the firm also faces some risks. UBS maintains a neutral recommendation following a downgrade tied to potential margin challenges in a potential Trump presidency. Concerns about high medical care ratios impacting Q1 earnings, and downgraded price targets from TD Cowen and Barclays have been reported. Nonetheless, Molina Healthcare's solid fundamentals suggest it may continue riding momentum in the near future.
Molina Healthcare MOH News Analytics from Fri, 30 Jun 2023 07:00:00 GMT to Thu, 09 May 2024 15:28:42 GMT -
Rating 7
- Innovation 5
- Information 9
- Rumor 5
